Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide. Current first line therapies target modulation of the monoamine system. A large variety of agents are currently available that effectively alter monoamine levels; however, approximately one third of MDD patients remain treatment refractory after adequate trials of multiple monoamine based therapies. Therefore, patients with treatment-resistant depression (TRD) may require modulation of pathways outside of the classic monoamine system. The purpose of this review was thus to discuss novel targets for TRD, to describe their potential mechanisms of action, the available clinical evidence for these targets, the limitations of available evidence as well as future research directions. Several alternate pathways involved in the patho-etiology of TRD have been uncovered including the following: inflammatory pathways, the oxidative stress pathway, the hypothalamic-pituitary-adrenal (HPA) axis, the metabolic and bioenergetics system, neurotrophic pathways, the glutamate system, the opioid system and the cholinergic system. For each of these systems, several targets have been assessed in preclinical and clinical models. Preclinical models strongly implicate these pathways in the patho-etiology of MDD. Clinical trials for TRD have been conducted for several novel targets; however, most of the trials discussed are small and several are uncontrolled. Therefore, further clinical trials are required to assess the true efficacy of these targets for TRD. As well, several promising novel agents have been clinically tested in MDD populations, but have yet to be assessed specifically for TRD. Thus, their applicability to TRD remains unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“Therefore, one may hypothesize that the deleterious mood effects of cortisol may outweigh the potential positive mood effects that may occur through cortisol’s anti-inflammatory effects [35, 87].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Miller, G. E., Chen, E., & Zhou, E. S. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.1.25 · Cited by 2,467 · cited 1×
“Numerous feedback loops are in place to regulate the levels of adrenal hormones as an excess or a shortfall may have profound effects such as seen in Cushing’s syndrome and Addison’s disease, respectively [80].”
BackgroundBrain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Neurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195
Omega-3 fatty acids in health and disease and in growth and development.
Simopoulos, A. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.3.438 · Cited by 2,162 · cited 1×
“Omega-3 polyunsaturated fatty acids are dietary fatty acids that cannot be endogenously produced by humans [51].”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Preclinical models have shown that the anti-depressant affect of NMDA antagonists may be through antagonism of NMDA receptors on GABAergic interneurons which reduce the inhibition of pyramidal cells leading to increased release of glutamate on non-NMDA receptors, notably AMPA receptors, in the prefrontal cortex [148].”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 5×
“A relative decrease in neurotrophins centrally and peripherally has been implicated in the pathoetiology of MDD [126].”
BackgroundInfluentialRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 3×
“>50% reduction in HAM-D scores versus only 33% in the placebo group [41].”
BackgroundCytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365 · cited 1×
“Moreover, the induction of an inflammatory state in pre-clinical and clinical models has repeatedly demonstrated mood symptoms, namely, poor mood, poor cognition, poor sleep and anhedonia [9, 21, 24-28].”
Background
Cited by
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationDandekar, M. P., Fenoy, A. J., Carvalho, A. F., Soares, J. C., & Quevedo, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2018.2 · Cited by 266
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
McIntyre, R. S., Carvalho, I. P., Lui, L. M. W., Majeed, A., Masand, P. S., Gill, H., Rodrigues, N. B., Lipsitz, O., Coles, A. C., Lee, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.06.050 · Cited by 187
Self-citationCholinergic regulation of mood: from basic and clinical studies to emerging therapeutics
Dulawa, S. C., & Janowsky, D. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0219-x · Cited by 187
Metadata
- Authors
- D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-10-13
- Volume
- 13
- Issue
- 5
- Pages
- 636-655
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2327348530
- Cited by
- 71
- References
- 69
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. https://app.cochat.ai/papers/10.2174/1570159x13666150630175044
- The paper
- D. Rosenblat, J., S. McIntyre, R., S. Alves, G., N. Fountoulakis, K., & F. Carvalho, A. (2015). Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666150630175044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.